HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| Line 2,459: | Line 2,459: | ||
Karin Miller, MD | Karin Miller, MD | ||
|3/25/2024 | |3/25/2024 | ||
| || | | ||Pending | ||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,550: | Line 2,551: | ||
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD | |[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD | ||
|3/22/2024 | |3/22/2024 | ||
| | |follow-up needed | ||
| || ||SK|| || | |||
|Sézary Syndrome | |Sézary Syndrome | ||
|Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | |Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | ||
| Line 2,597: | Line 2,599: | ||
Andrew Siref, MD | Andrew Siref, MD | ||
|10/14/2025 | |10/14/2025 | ||
| | |11/24/2025 | ||
|Pending | |||
| ||SK|| || | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,607: | Line 2,610: | ||
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD | |[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD | ||
|3/22/2024 | |3/22/2024 | ||
| || || ||SK|| || | |follow-up needed|| || ||SK|| || | ||
|Mycosis Fungoides | |Mycosis Fungoides | ||
|Jane Scribner, MD and Daynna J. Wolff, PhD | |Jane Scribner, MD and Daynna J. Wolff, PhD | ||
| Line 2,617: | Line 2,620: | ||
Shashirekha Shetty, PhD | Shashirekha Shetty, PhD | ||
|7/1/2024 | |7/1/2024 | ||
| | |follow-up needed | ||
| | | | ||
| ||SK|| || | | ||SK|| || | ||
| Line 2,628: | Line 2,631: | ||
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); | ||
Shashirekha Shetty, PhD | Shashirekha Shetty, PhD | ||
|7/1/2024|| | |7/1/2024||follow-up needed | ||
| | | | ||
| ||SK|| || | | ||SK|| || | ||
| Line 2,639: | Line 2,642: | ||
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee) | |[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee) | ||
|3/19/2024 | |3/19/2024 | ||
| | |follow-up needed | ||
| | |||
| ||SK|| || | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,662: | Line 2,666: | ||
Andrew Siref, MD | Andrew Siref, MD | ||
|10/14/2025|| | |10/14/2025||11/24/2025 | ||
|Pending | |||
| ||SK|| || | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,800: | Line 2,805: | ||
|- | |- | ||
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | |[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | ||
| | |follow-up needed | ||
| || ||SK|| ||prior authors not available | |||
|Angioimmunoblastic T-cell Lymphoma | |Angioimmunoblastic T-cell Lymphoma | ||
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | |Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | ||
| Line 2,808: | Line 2,814: | ||
|- | |- | ||
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | |[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | ||
| | |follow-up needed | ||
| || ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||